Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 13;13:1016647. doi: 10.3389/fimmu.2022.1016647

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wang, Wang, Xiang, Deng, Xu, He, Pu, Wang, Fan and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Laboratory examination results during the clinical course. (A) Trends in the level of tumor markers, including CA 199, CA125, and CEA (right Y-axis) correspond to the treatment timeline. (B) Trends in the level of weight changes corresponding to the treatment timeline. (C). Trends in the level of blood routine examination, including PLT, HBC, and WBC (right Y-axis) correspond to the treatment timeline. (D) Trends in the level of biochemical indicators, including ALT, AST, and Bilirubin (right Y-axis) correspond to the treatment timeline. All X-axes show the date of disease progression. (CEA, carcinoembryonic antigen; CA199, carbohydrate antigen 19-9; CA125, carbohydrate antigen 125, WBC, white blood cell count; HBC, hemoglobin; PLT, blood platelet count, ALT, alanine aminotransferase; AST, aspartate aminotransferase).